Guidelines on the use of extracorporeal photopheresis

Journal of the European Academy of Dermatology and Venereology

Volumn 28, Issue SUPPL. 1, 2014, Pages 1-37

  Knobler, R ^a   Berlin, G ^b   Calzavara Pinton, P ^c   Greinix, H ^d   Jaksch, P ^d   Laroche, L ^e   Ludvigsson, J ^f   Quaglino, P ^g   Reinisch, W ^d   Scarisbrick, J ^h   Schwarz, T ⁱ   Wolf, P ^j   Arenberger, P ^k   Assaf, C ^l   Bagot, M ^m   Barr, M ⁿ   Bohbot, A ^o   Bruckner Tuderman, L ^p   Dreno, B ^q   Enk, A ^r   French, L ^s   Gniadecki, R ^t   Gollnick, H ^u   Hertl, M ^v   Jantschitsch, C ^w   Jung, A ^x   Just, U ^a   Klemke, C D ^x   Lippert, U ^w   Luger, T ^y   Papadavid, E ^z   Pehamberger, H ^a   Ranki, A ^aa   Stadler, R ^ab   Sterry, W ^ac   Wolf, I H ^j   Worm, M ^ac   Zic, J ^ad   Zouboulis, C C ^w   Hillen, U ^ae   more..

^a Universitatsklinik fur Dermatologie   (Austria)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^c SPEDALI CIVILI   (Italy)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e AVICENNE HOSPITAL   (France)

^f LINKÖPING UNIVERSITY   (Sweden)

^g UNIVERSITY OF TURIN   (Italy)

^h UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

ⁱ UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^j MEDICAL UNIVERSITY OF GRAZ   (Austria)

^k CHARLES UNIVERSITY   (Czech Republic)

^l HELIOS KLINIKUM KREFELD   (Germany)

^m SAINT LOUIS HOSPITAL   (France)

ⁿ UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^o UNIVERSITÉ DE STRASBOURG   (France)

^p UNIVERSITY OF FREIBURG   (Germany)

^q NANTES UNIVERSITY HOSPITAL   (France)

^r UNIVERSITY OF HEIDELBERG   (Germany)

^s UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^t BISPEBJERG HOSPITAL   (Denmark)

^u OTTO VON GUERICKE UNIVERSITY   (Germany)

^v UNIVERSITY HOSPITAL MARBURG   (Germany)

^w DESSAU MEDICAL CENTER   (Germany)

^x UNIVERSITY OF HEIDELBERG   (Germany)

^y UNIVERSITY OF MÜNSTER   (Germany)

^z UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^aa HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^ab KLINIKUM MINDEN   (Germany)

^ac CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^ad VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^ae UNIVERSITY OF DUISBURG ESSEN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; HEPARIN; METHOXSALEN;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; ATOPIC DERMATITIS; CELL DIFFERENTIATION; CELL POPULATION; CELL SEPARATION; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); CROHN DISEASE; CUTANEOUS T CELL LYMPHOMA; DISEASE COURSE; EPIDERMOLYSIS BULLOSA ACQUISITA; EXTRACORPOREAL PHOTOPHERESIS; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEART TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; LICHEN PLANUS; LUNG TRANSPLANTATION; LUPUS ERYTHEMATOSUS; PATIENT SELECTION; PEMPHIGUS; PHASE 2 CLINICAL TRIAL (TOPIC); PHOTOACTIVATION; PHOTOTHERAPY; PRIORITY JOURNAL; SCLERODERMA; STEROID THERAPY; SYSTEMATIC REVIEW; SYSTEMIC SCLEROSIS; THERAPY EFFECT; TIME TO TREATMENT; TREATMENT DURATION; ULTRAVIOLET A RADIATION;

AUTOIMMUNE DISEASES; GRAFT REJECTION; GRAFT VS HOST DISEASE; HUMANS; INFLAMMATORY BOWEL DISEASES; LYMPHOMA, T-CELL, CUTANEOUS; PHOTOPHERESIS; PHOTOSENSITIZING AGENTS; SCLERODERMA, SYSTEMIC; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84893209197     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12311     Document Type: Article

References (308)

1. Knobler R, Barr ML, Couriel DR et al. Extracorporeal photopheresis: past, present, and future. J Am Acad Dermatol 2009; 61: 652-665.
2. Schooneman F. Extracorporeal photopheresis technical aspects. Transfus Apher Sci 2003; 28: 51-61.
3. Geskin L. ECP versus PUVA for the treatment of cutaneous T-cell lymphoma. Skin Therapy Lett 2007; 12: 1-4.
4. Knobler RM, Trautinger F, Graninger W et al. Parenteral administration of 8-methoxypsoralen in photopheresis. J Am Acad Dermatol 1993; 28: 580-584.
5. Edelson R, Berger C, Gasparro F et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy preliminary results. N Engl J Med 1987; 316: 297-303.
6. Trautinger F, Just U, Knobler R. Photopheresis (extracorporeal photochemotherapy). Photochem Photobiol Sci 2012; 12: 22-28.
7. Wong ECC, Jacobsohn D. ECP in children and adolescents. In Greinix H, Knobler R, eds. Extracorporeal photopheresis. Walter de Gruyter GmbH & Co. KG, Berlin/Boston, 2012: 8-21.
8. Bladon J, Taylor PC. Extracorporeal photopheresis induces apoptosis in the lymphocytes of cutaneous T-cell lymphoma and graft-versus-host disease patients. Br J Haematol 1999; 107: 707-711.
9. Gerber A, Bohne M, Rasch J, Struy H, Ansorge S, Gollnick H. Investigation of annexin V binding to lymphocytes after extracorporeal photoimmunotherapy as an early marker of apoptosis. Dermatology 2000; 201: 111-117.
10. Voss CY, Fry TJ, Coppes MJ, Blajchman MA. Extending the horizon for cell-based immunotherapy by understanding the mechanisms of action of photopheresis. Transfus Med Rev 2010; 24: 22-32.
11. Goussetis E, Varela I, Tsirigotis P. Update on the mechanism of action and on clinical efficacy of extracorporeal photopheresis in the treatment of acute and chronic graft versus host disease in children. Transfus Apher Sci 2012; 46: 203-209.
12. Wolnicka-Glubisz A, Fraczek J, Skrzeczynska-Moncznik J et al. Effect of UVA and 8-methoxypsoralen, 4, 6, 4'-trimethylangelicin or chlorpromazine on apoptosis of lymphocytes and their recognition by monocytes. J Physiol Pharmacol 2010; 61: 107-114.
13. Berger CL, Hanlon D, Kanada D, Girardi M, Edelson RL. Transimmunization, a novel approach for tumor immunotherapy. Transfus Apher Sci 2002; 26: 205-216.
14. Hannani D, Gabert F, Laurin D et al. Photochemotherapy induces the apoptosis of monocytes without impairing their function. Transplantation 2010; 89: 492-499.
15. Spisek R, Gasova Z, Bartunkova J. Maturation state of dendritic cells during the extracorporeal photopheresis and its relevance for the treatment of chronic graft-versus-host disease. Transfusion 2006; 46: 55-65.
16. Girardi M, Berger CL, Wilson LD et al. Transimmunization for cutaneous T cell lymphoma: a Phase I study. Leuk Lymphoma 2006; 47: 1495-1503.
17. Fimiani M, Rubegni P, Pimpinelli N, Mori M, De Aloe G, Andreassi L. Extracorporeal photochemotherapy induces a significant increase in CD36 + circulating monocytes in patients with mycosis fungoides. Dermatology 1997; 194: 107-110.
18. Di Renzo M, Rubegni P, De Aloe G et al. Extracorporeal photochemotherapy restores Th1/Th2 imbalance in patients with early stage cutaneous T-cell lymphoma. Immunology 1997; 92: 99-103.
19. Bladon J, Taylor PC. Extracorporeal photopheresis: a focus on apoptosis and cytokines. J Dermatol Sci 2006; 43: 85-94.
20. Merlin E, Goncalves-Mendes N, Hannani D et al. Extracorporeal photochemotherapy induces arginase 1 in patients with graft versus host disease. Transplant Immunol 2011; 24: 100-106.
21. Maeda A, Schwarz A, Kernebeck K et al. Intravenous infusion of syngeneic apoptotic cells by photopheresis induces antigen-specific regulatory T cells. J Immunol 2005; 174: 5968-5976.
22. Maeda A, Beissert S, Schwarz T, Schwarz A. Phenotypic and functional characterization of ultraviolet radiation-induced regulatory T cells. J Immunol 2008; 180: 3065-3071.
23. Maeda A, Schwarz A, Bullinger A, Morita A, Peritt D, Schwarz T. Experimental extracorporeal photopheresis inhibits the sensitization and effector phases of contact hypersensitivity via two mechanisms: generation of IL-10 and induction of regulatory T cells. J Immunol 2008; 181: 5956-5962.
24. Whittle R, Taylor PC. Circulating B-cell activating factor level predicts clinical response of chronic graft-versus-host disease to extracorporeal photopheresis. Blood 2011; 118: 6446-6449.
25. Gatza E, Rogers CE, Clouthier SG et al. Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells. Blood 2008; 112: 1515-1521.
26. Rezvani K, Mielke S, Ahmadzadeh M et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 2006; 108: 1291-1297.
27. Wolf D, Wolf AM, Fong D et al. Regulatory T-cells in the graft and the risk of acute graft-versus-host disease after allogeneic stem cell transplantation. Transplantation 2007; 83: 1107-1113.
28. Zhai Z, Sun Z, Li Q et al. Correlation of the CD4 + CD25high T-regulatory cells in recipients and their corresponding donors to acute GVHD. Transpl Int 2007; 20: 440-446.
29. Quaglino P, Comessatti A, Ponti R et al. Reciprocal modulation of circulating CD4 + CD25 + bright T cells induced by extracorporeal photochemotherapy in cutaneous T-cell lymphoma and chronic graft-versushost- disease patients. Int J Immunopathol Pharmacol 2009; 22: 353-362.
30. Rao V, Saunes M, Jorstad S, Moen T. Cutaneous T cell lymphoma and graft-versus-host disease: a comparison of in vivo effects of extracorporeal photochemotherapy on Foxp3 + regulatory T cells. Clin Immunol 2009; 133: 303-313.
31. Di Biaso I, Di Maio L, Bugarin C et al. Regulatory T cells and extracorporeal photochemotherapy: correlation with clinical response and decreased frequency of proinflammatory T cells. Transplantation 2009; 87: 1422-1425.
32. Schmitt S, Johnson TS, Karakhanova S, Naher H, Mahnke K, Enk AH. Extracorporeal photophoresis augments function of CD4 + CD25 + FoxP3 + regulatory T cells by triggering adenosine production. Transplantation 2009; 88: 411-416.
33. Tsirigotis P, Kapsimalli V, Baltadakis I et al. Extracorporeal photopheresis in refractory chronic graft-versus-host disease: the influence on peripheral blood T cell subpopulations. A study by the Hellenic Association of Hematology. Transfus Apher Sci 2012; 46: 181-188.
34. Biagi E, Di Biaso I, Leoni V et al. Extracorporeal photochemotherapy is accompanied by increasing levels of circulating CD4 + CD25 + GITR+ Foxp3 + CD62L+ functional regulatory T-cells in patients with graft-versus-host disease. Transplantation 2007; 84: 31-39.
35. Heid JB, Schmidt A, Oberle N et al. FOXP3 + CD25- tumor cells with regulatory function in Sezary syndrome. J Invest Dermatol 2009; 129: 2875-2885.
36. Klemke CD, Fritzsching B, Franz B et al. Paucity of FOXP3 + cells in skin and peripheral blood distinguishes Sezary syndrome from other cutaneous T-cell lymphomas. Leukemia 2006; 20: 1123-1129.
37. Tiemessen MM, Mitchell TJ, Hendry L, Whittaker SJ, Taams LS, John S. Lack of suppressive CD4 + CD25 + FOXP3 + T cells in advanced stages of primary cutaneous T-cell lymphoma. J Invest Dermatol 2006; 126: 2217-2223.
38. George JF, Gooden CW, Guo L, Kirklin JK. Role for CD4(+)CD25(+) T cells in inhibition of graft rejection by extracorporeal photopheresis. J Heart Lung Transplant 2008; 27: 616-622.
39. Reinisch W, Nahavandi H, Santella R et al. Extracorporeal photochemotherapy in patients with steroid-dependent Crohn's disease: a prospective pilot study. Aliment Pharmacol Ther 2001; 15: 1313-1322.
40. Garrett WS, Gordon JI, Glimcher LH. Homeostasis and inflammation in the intestine. Cell 2010; 140: 859-870.
41. Ludvigsson J, Samuelsson U, Ernerudh J, Johansson C, Stenhammar L, Berlin G. Photopheresis at onset of type 1 diabetes: a randomised, double blind, placebo controlled trial. Arch Dis Child 2001; 85: 149-154.
42. Ernerudh J, Ludvigsson J, Berlin G, Samuelsson U. Effect of photopheresis on lymphocyte population in children with newly diagnosed type 1 diabetes. Clin Diagn Lab Immunol 2004; 11: 856-861.
43. Faresjo MK, Ernerudh J, Berlin G, Garcia J, Ludvigsson J. The immunological effect of photopheresis in children with newly diagnosed type 1 diabetes. Pediatr Res 2005; 58: 459-466.
44. Jonson CO, Pihl M, Nyholm C, Cilio CM, Ludvigsson J, Faresjo M. Regulatory T cell-associated activity in photopheresis-induced immune tolerance in recent onset type 1 diabetes children. Clin Exp Immunol 2008; 153: 174-181.
45. Dummer R, Assaf C, Bagot M et al. Maintenance therapy in cutaneous T-cell lymphoma: who, when, what? Eur J Cancer 2007; 43: 2321-2329.
46. Olsen E, Vonderheid E, Pimpinelli N et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 1713-1722.
47. Trautinger F, Knobler R, Willemze R et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome. Eur J Cancer 2006; 42: 1014-1030.
48. Knobler R, Duvic M, Querfeld C et al. Long-term follow-up and survival of cutaneous T-cell lymphoma patients treated with extracorporeal photopheresis. Photodermatol Photoimmunol Photomed 2012; 28: 250-257.
49. Zic JA. The treatment of cutaneous T-cell lymphoma with photopheresis. Dermatol Ther 2003; 16: 337-346.
50. Scarisbrick JJ, Taylor P, Holtick U et al. U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease. Br J Dermatol 2008; 158: 659-678.
51. Tsirigotis P, Pappa V, Papageorgiou S et al. Extracorporeal photopheresis in combination with bexarotene in the treatment of mycosis fungoides and Sezary syndrome. Br J Dermatol 2007; 156: 1379-1381.
52. Arulogun S, Prince HM, Gambell P et al. Extracorporeal photopheresis for the treatment of Sezary syndrome using a novel treatment protocol. J Am Acad Dermatol 2008; 59: 589-595.
53. Booken N, Weiss C, Utikal J, Felcht M, Goerdt S, Klemke CD. Combination therapy with extracorporeal photopheresis, interferon-alpha, PUVA and topical corticosteroids in the management of Sezary syndrome. J Dtsch Dermatol Ges 2010; 8: 428-438.
54. McGirt LY, Thoburn C, Hess A, Vonderheid EC. Predictors of response to extracorporeal photopheresis in advanced mycosis fungoides and Sezary syndrome. Photodermatol Photoimmunol Photomed 2010; 26: 182-191.
55. Talpur R, Demierre MF, Geskin L et al. Multicenter photopheresis intervention trial in early-stage mycosis fungoides. Clin Lymphoma Myeloma Leuk 2011; 11: 219-227.
56. Raphael BA, Shin DB, Suchin KR et al. High clinical response rate of Sezary syndrome to immunomodulatory therapies: prognostic markers of response. Arch Dermatol 2011; 147: 1410-1415.
57. Quaglino P, Knobler R, Fierro MT et al. Extracorporeal photopheresis for the treatment of erythrodermic cutaneous T-cell lymphoma: a single center clinical experience with long-term follow-up data and a brief over-view of the literature. Int J Dermatol 2013; 52: 1308-1318 (in press).
58. Kim YH, Bishop K, Varghese A, Hoppe RT. Prognostic factors in erythrodermic mycosis fungoides and the Sezary syndrome. Arch Dermatol 1995; 131: 1003-1008.
59. Heald PW, Perez MI, Christensen I, Dobbs N, McKiernan G, Edelson R. Photopheresis therapy of cutaneous T-cell lymphoma: the Yale-New Haven Hospital experience. Yale J Biol Med 1989; 62: 629-638.
60. Gottlieb SL, Wolfe JT, Fox FE et al. Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution. J Am Acad Dermatol 1996; 35: 946-957.
61. Zic JA, Stricklin GP, Greer JP et al. Long-term follow-up of patients with cutaneous T-cell lymphoma treated with extracorporeal photochemotherapy. J Am Acad Dermatol 1996; 35: 935-945.
62. Suchin KR, Cucchiara AJ, Gottleib SL et al. Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institution. Arch Dermatol 2002; 138: 1054-1060.
63. Duvic M, Chiao N, Talpur R. Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma. J Cutan Med Surg 2003; 7(4 Suppl): 3-7.
64. Wollina U, Looks A, Meyer J et al. Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial. J Am Acad Dermatol 2001; 44: 253-260.
65. Bisaccia E, Gonzalez J, Palangio M, Schwartz J, Klainer AS. Extracorporeal photochemotherapy alone or with adjuvant therapy in the treatment of cutaneous T-cell lymphoma: a 9-year retrospective study at a single institution. J Am Acad Dermatol 2000; 43: 263-271.
66. Wilson LD, Jones GW, Kim D et al. Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides. J Am Acad Dermatol 2000; 43: 54-60.
67. Whittaker SJ, Marsden JR, Spittle M,Russell Jones R. Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas. Br J Dermatol 2003; 149: 1095-1107.
68. National Cancer Institute: PDQ®. Mycosis Fungoides and the Śezary Syndrome Treatment. Bethesda, MD: National Cancer Institute. Available at: http://cancer.gov/cancertopics/pdq/treatment/mycosisfungoides/ HealthProfessional. (last accessed: 31 October 2013).
69. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: non-Hodgkin's lymphomas - version 3. URL http://www.nccn.org (last accessed: 30 October 2013).
70. Miller JD, Kirkland EB, Domingo DS et al. Review of extracorporeal photopheresis in early-stage (IA, IB, and IIA) cutaneous T-cell lymphoma. Photodermatol Photoimmunol Photomed 2007; 23: 163-171.
71. Knobler R, Jantschitsch C. Extracorporeal photochemoimmunotherapy in cutaneous T-cell lymphoma. Transfus Apher Sci 2003; 28: 81-89.
72. Berger C, Hoffmann K, Vasquez JG et al. Rapid generation of maturationally synchronized human dendritic cells: contribution to the clinical efficacy of extracorporeal photochemotherapy. Blood 2010; 116: 4838-4847.
73. Evans AV, Wood BP, Scarisbrick JJ et al. Extracorporeal photopheresis in Sezary syndrome: hematologic parameters as predictors of response. Blood 2001; 98: 1298-1301.
74. McKenna KE, Whittaker S, Rhodes LE et al. Evidence-based practice of photopheresis 1987-2001: a report of a workshop of the British Photodermatology Group and the U.K. Skin Lymphoma Group. Br J Dermatol 2006; 154: 7-20.
75. Olsen EA, Rook AH, Zic J et al. Sezary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am Acad Dermatol 2011; 64: 352-404.
76. Clement F, Read C, Taylor P, Broughton S. A review of extracorporeal photopheresis for cancer and other diseases - version 3. URL http:// www.sheffield.nhs.uk/policies/resources/norcom/ extracorporealphotopheresisforcancer. pdf (last accessed: 30 October 2013).
77. Stadler R, Assaf C, Klemke C-D et al. S2k Kurzleitlinie Kutane Lymphome, AWMF 2012, Registernummer 032-027.
78. Olsen EA, Whittaker S, Kim YH et al. Clinical end points and response criteria in mycosis fungoides and Sezary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol 2011; 29: 2598-2607.
79. Socie G, Stone JV, Wingard JR et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med 1999; 341: 14-21.
80. Lee SJ, Klein JP, Barrett AJ et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 2002; 100: 406-414.
81. Higman MA, Vogelsang GB. Chronic graft versus host disease. Br J Haematol 2004; 125: 435-454.
82. Horwitz ME, Sullivan KM. Chronic graft-versus-host disease. Blood Rev 2006; 20: 15-27.
83. Lee SJ. New approaches for preventing and treating chronic graft-versus- host disease. Blood 2005; 105: 4200-4206.
84. Wolff D, Gerbitz A, Ayuk F et al. Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. Biol Blood Marrow Transplant 2010; 16: 1611-1628.
85. Wolff D, Schleuning M, von Harsdorf S et al. Consensus conference on clinical practice in chronic GVHD: second-line treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2011; 17: 1-17.
86. Martin PJ, Inamoto Y, Carpenter PA, Lee SJ, Flowers ME. Treatment of chronic graft-versus-host disease: past, present and future. Korean J Hematol 2011; 46: 153-163.
87. Rossetti F, Dall'Amico R, Grovetti G et al. Extracorporeal photochemotherapy for the treatment of graft-versus-host disease. Bone Marrow Transplant 1996; 18(Suppl 2): 175-181.
88. Dall'Amico R, Rossetti F, Zulian F et al. Photopheresis in paediatric patients with drug-resistant chronic graft-versus-host disease. Br J Haematol 1997; 97: 848-854.
89. Salvaneschi L, Perotti C, Zecca M et al. Extracorporeal photochemotherapy for treatment of acute and chronic GVHD in childhood. Transfusion 2001; 41: 1299-1305.
90. Halle P, Paillard C, D'Incan M et al. Successful extracorporeal photochemotherapy for chronic graft-versus-host disease in pediatric patients. J Hematother Stem Cell Res 2002; 11: 501-512.
91. Perseghin P, Dassi M, Balduzzi A, Rovelli A, Bonanomi S, Uderzo C. Mononuclear cell collection in patients undergoing extra-corporeal photo-chemotherapy for acute and chronic graft-vs.-host-disease (GvHD): comparison between COBE Spectra version 4.7 and 6.0 (AutoPBSC). J Clin Apher 2002; 17: 65-71.
92. Perutelli P, Rivabella L, Lanino E, Pistoia V, Dini G. ATP downregulation in mononuclear cells from children with graft-versus-host disease following extracorporeal photochemotherapy. Haematologica 2002; 87: 335-336.
93. Messina C, Locatelli F, Lanino E et al. Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation. Br J Haematol 2003; 122: 118-127.
94. Duzovali O, Chan KW. Intensive extracorporeal photochemotherapy in pediatric patients with chronic graft-versus-host disease (cGVHD). Pediatr Blood Cancer 2007; 48: 218-221.
95. Kanold J, Merlin E, Halle P et al. Photopheresis in pediatric graft-versus- host disease after allogeneic marrow transplantation: clinical practice guidelines based on field experience and review of the literature. Transfusion 2007; 47: 2276-2289.
96. Perseghin P, Galimberti S, Balduzzi A et al. Extracorporeal photochemotherapy for the treatment of chronic graft-versus-host disease: trend for a possible cell dose-related effect? Ther Apher Dial 2007; 11: 85-93.
97. Gonzalez-Vicent M, Ramirez M, Perez A, Lassaletta A, Sevilla J, Diaz MA. Extracorporeal photochemotherapy for steroid-refractory graft-versus-host disease in low-weight pediatric patients. Immunomodulatory effects and clinical outcome. Haematologica 2008; 93: 1278-1280.
98. Perotti C, Del Fante C, Tinelli C et al. Extracorporeal photochemotherapy in graft-versus-host disease: a longitudinal study on factors influencing the response and survival in pediatric patients. Transfusion 2010; 50: 1359-1369.
99. Greinix HT, Volc-Platzer B, Rabitsch W et al. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood 1998; 92: 3098-3104.
100. Apisarnthanarax N, Donato M, Korbling M et al. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroiddependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results. Bone Marrow Transplant 2003; 31: 459-465.
101. Seaton ED, Szydlo RM, Kanfer E, Apperley JF, Russell-Jones R. Influence of extracorporeal photopheresis on clinical and laboratory parameters in chronic graft-versus-host disease and analysis of predictors of response. Blood 2003; 102: 1217-1223.
102. Foss FM, DiVenuti GM, Chin K et al. Prospective study of extracorporeal photopheresis in steroid-refractory or steroid-resistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factors. Bone Marrow Transplant 2005; 35: 1187-1193.
103. Rubegni P, Cuccia A, Sbano P et al. Role of extracorporeal photochemotherapy in patients with refractory chronic graft-versus-host disease. Br J Haematol 2005; 130: 271-275.
104. Couriel DR, Hosing C, Saliba R et al. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood 2006; 107: 3074-3080.
105. Greinix HT, Socie G, Bacigalupo A et al. Assessing the potential role of photopheresis in hematopoietic stem cell transplant. Bone Marrow Transplant 2006; 38: 265-273.
106. Flowers ME, Apperley JF, van Besien K et al. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood 2008; 112: 2667-2674.
107. Dignan FL, Greenblatt D, Cox M et al. Efficacy of bimonthly extracorporeal photopheresis in refractory chronic mucocutaneous GVHD. Bone Marrow Transplant 2012; 47: 824-830.
108. Greinix HT, van Besien K, Elmaagacli AH et al. Progressive improvement in cutaneous and extracutaneous chronic graft-versus-host disease after a 24-week course of extracorporeal photopheresis-results of a crossover randomized study. Biol Blood Marrow Transplant 2011; 17: 1775-1782.
109. Owsianowski M, Gollnick H, Siegert W, Schwerdtfeger R, Orfanos CE. Successful treatment of chronic graft-versus-host disease with extracorporeal photopheresis. Bone Marrow Transplant 1994; 14: 845-848.
110. Dignan FL, Amrolia P, Clark A et al. Diagnosis and management of chronic graft-versus-host disease. Br J Haematol 2012; 158: 46-61.
111. Kanold J, Messina C, Halle P et al. Update on extracorporeal photochemotherapy for graft-versus-host disease treatment. Bone Marrow Transplant 2005; 35(Suppl 1): S69-S71.
112. Marshall SR. Technology insight: ECP for the treatment of GvHD-can we offer selective immune control without generalized immunosuppression? Nat Clin Pract Oncol 2006; 3: 302-314.
113. Smith EP, Sniecinski I, Dagis AC et al. Extracorporeal photochemotherapy for treatment of drug-resistant graft-vs.-host disease. Biol Blood Marrow Transplant 1998; 4: 27-37.
114. Kanold J, Paillard C, Halle P, D'Incan M, Bordigoni P, Demeocq F. Extracorporeal photochemotherapy for graft versus host disease in pediatric patients. Transfus Apher Sci 2003; 28: 71-80.
115. Jagasia MH, Savani BN, Stricklin G et al. Classic and overlap chronic graft-versus-host disease (cGVHD) is associated with superior outcome after extracorporeal photopheresis (ECP). Biol Blood Marrow Transplant 2009; 15: 1288-1295.
116. Dall'Amico R, Messina C. Extracorporeal photochemotherapy for the treatment of graft-versus-host disease. Ther Apher 2002; 6: 296-304.
117. Child FJ, Ratnavel R, Watkins P et al. Extracorporeal photopheresis (ECP) in the treatment of chronic graft-versus-host disease (GVHD). Bone Marrow Transplant 1999; 23: 881-887.
118. Lucid CE, Savani BN, Engelhardt BG et al. Extracorporeal photopheresis in patients with refractory bronchiolitis obliterans developing after allo- SCT. Bone Marrow Transplant 2011; 46: 426-429.
119. Greinix HT, Volc-Platzer B, Kalhs P et al. Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versushost disease: a pilot study. Blood 2000; 96: 2426-2431.
120. Bisaccia E, Palangio M, Gonzalez J et al. Treatment of extensive chronic graft-versus-host disease with extracorporeal photochemotherapy. J Clin Apher 2006; 21: 181-187.
121. Filipovich AH, Weisdorf D, Pavletic S et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945-956.
122. Pavletic SZ, Martin P, Lee SJ et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant 2006; 12: 252-266.
123. Martin PJ, Rizzo JD, Wingard JR et al. First and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2012; 18: 1150-1163.
124. Martin PJ, Schoch G, Fisher L et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 1990; 76: 1464-1472.
125. Pidala J, Anasetti C. Glucocorticoid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2010; 16: 1504-1518.
126. Dignan FL, Clark A, Amrolia P et al. Diagnosis and management of acute graft-versus-host disease. Brit J Haematol 2012; 158: 30-45.
127. Perseghin P. Extracorporeal photochemotherapy as a challenging treatment for cutaneous T-cell lymphoma, acute and chronic graft-versushost disease, organ rejection and T-lymphocyte-mediated autoimmune diseases. Transfus Med Hemother 2008; 35: 8-17.
128. Greinix HT, Worel N, Knobler R. Role of extracorporeal photopheresis (ECP) in treatment of steroid-refractory acute graft-verus-host disease. Biol Blood Marrow Transplant 2010; 16: 1747-1748.
129. Greinix HT, Knobler RM, Worel N et al. The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. Haematologica 2006; 91: 405-408.
130. Garban F, Drillat P, Makowski C et al. Extracorporeal chemophototherapy for the treatment of graft-versus-host disease: hematologic consequences of short-term, intensive courses. Haematologica 2005; 90: 1096-1101.
131. Perfetti P, Carlier P, Strada P et al. Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD. Bone Marrow Transplant 2008; 42: 609-617.
132. Berger M, Pessolano R, Albiani R et al. Extracorporeal photopheresis for steroid resistant graft versus host disease in pediatric patients: a pilot single institution report. J Pediatr Hematol Oncol 2007; 29: 678-687.
133. Calore E, Calo A, Tridello G et al. Extracorporeal photochemotherapy may improve outcome in children with acute GVHD. Bone Marrow Transplant 2008; 42: 421-425.
134. Schneiderman J, Jacobsohn DA, Collins J, Thormann K, Kletzel M. The use of fluid boluses to safely perform extracorporeal photopheresis (ECP) in low-weight children: a novel procedure. J Clin Apher 2010; 25: 63-69.
135. Das-Gupta E, Watson J, Byrne J, Russell N. A single centre experience of the efficacy of extracorporeal photopheresis in the treatment of steroidrefractory acute graft-versus-host disease. Bone Marrow Transplant 2011; 46: S114(P503).
136. Miller KB, Roberts TF, Chan G et al. A novel reduced intensity regimen for allogeneic hematopoietic stem cell transplantation associated with a reduced incidence of graft-versus-host disease. Bone Marrow Transplant 2004; 33: 881-889.
137. Shaughnessy PJ, Bolwell BJ, van Besien K et al. Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2009; 45: 1068-1076.
138. Schwartz J, Winters JL, Padmanabhan A et al. Clinical applications of therapeutic apheresis: an evidence based approach, 6th edition. J Clin Apheresis 2013; 28: 145-284.
139. MacMillan ML, Weisdorf DJ, Davies SM et al. Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant 2002; 8: 40-46.
140. Przepiorka D, Weisdorf D, Martin P et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828.
141. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus- host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
142. Jimenez SA. Scleroderma. URL http://www.medscape.com (last accessed: 30 October 2013)
143. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009; 360: 1989-2003.
144. Barnett AJ, Miller MH, Littlejohn GO. A survival study of patients with scleroderma diagnosed over 30 years (1953-1983): the value of a simple cutaneous classification in the early stages of the disease. J Rheumatol 1988; 15: 276-283.
145. Artlett CM, Smith JB, Jimenez SA. New perspectives on the etiology of systemic sclerosis. Mol Med Today 1999; 5: 74-78.
146. French LE, Alcindor T, Shapiro M et al. Identification of amplified clonal T cell populations in the blood of patients with chronic graft-versushost disease: positive correlation with response to photopheresis. Bone Marrow Transplant 2002; 30: 509-515.
147. Marie I, Cordel N, Lenormand B et al. Clonal T cells in the blood of patients with systemic sclerosis. Arch Dermatol 2005; 141: 88-89.
148. Kreuter A, Hoxtermann S, Tigges C, Hahn SA, Altmeyer P, Gambichler T. Clonal T-cell populations are frequent in the skin and blood of patients with systemic sclerosis. Br J Dermatol 2009; 161: 785-790.
149. Rook AH, Freundlich B, Jegasothy BV et al. Treatment of systemic sclerosis with extracorporeal photochemotherapy. Results of a multicenter trial. Arch Dermatol 1992; 128: 337-346.
150. Knobler RM, French LE, Kim Y et al. A randomized, double-blind, placebo- controlled trial of photopheresis in systemic sclerosis. J Am Acad Dermatol 2006; 54: 793-799.
151. Enomoto DN, Mekkes JR, Bossuyt PM et al. Treatment of patients with systemic sclerosis with extracorporeal photochemotherapy (photopheresis). J Am Acad Dermatol 1999; 41: 915-922.
152. Muellegger RR, Hofer A, Salmhofer W, Soyer HP, Kerl H, Wolf P. Extended extracorporeal photochemotherapy with extracorporeal administration of 8-methoxypsoralen in systemic sclerosis. An Austrian single-center study. Photodermatol Photoimmunol Photomed 2000; 16: 216-223.
153. Papp G, Horvath IF, Barath S et al. Immunomodulatory effects of extracorporeal photochemotherapy in systemic sclerosis. Clin Immunol 2012; 142: 150-159.
154. Neustadter JH, Samarin F, Carlson KR, Girardi M. Extracorporeal photochemotherapy for generalized deep morphea. Arch Dermatol 2009; 145: 127-130.
155. Christie JD, Edwards LB, Kucheryavaya AY et al. The Registry of the
156. Estenne M, Maurer JR, Boehler A et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002; 21: 297-310.
157. Boehler A, Estenne M. Post-transplant bronchiolitis obliterans. Eur Resp J 2003; 22: 1007-1018.
158. Mullen JC, Oreopoulos A, Lien DC et al. A randomized, controlled trial of daclizumab vs anti-thymocyte globulin induction for lung transplantation. J Heart Lung Transplant 2007; 26: 504-510.
159. Gottlieb J, Szangolies J, Koehnlein T, Golpon H, Simon A, Welte T. Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2008; 85: 36-41.
160. Bhorade SM, Stern E. Immunosuppression for lung transplantation. Proc Am Thorac Soc 2009; 6: 47-53.
161. Andreu G, Achkar A, Couetil JP et al. Extracorporeal photochemotherapy treatment for acute lung rejection episode. J Heart Lung Transplant 1995; 14: 793-796.
162. Slovis BS, Loyd JE, King LE Jr. Photopheresis for chronic rejection of lung allografts. N Engl J Med 1995; 332: 962.
163. O'Hagan AR, Stillwell PC, Arroliga A, Koo A. Photopheresis in the treatment of refractory bronchiolitis obliterans complicating lung transplantation. Chest 1999; 115: 1459-1462.
164. Villanueva J, Bhorade SM, Robinson JA, Husain AN, Garrity ER Jr. Extracorporeal photopheresis for the treatment of lung allograft rejection. Ann Transplant 2000; 5: 44-47.
165. Salerno CT, Park SJ, Kreykes NS et al. Adjuvant treatment of refractory lung transplant rejection with extracorporeal photopheresis. J Thorac Cardiovasc Surg 1999; 117: 1063-1069.
166. Benden C, Speich R, Hofbauer GF et al. Extracorporeal photopheresis after lung transplantation: a 10-year single-center experience. Transplantation 2008; 86: 1625-1627.
167. Morrell MR, Despotis GJ, Lublin DM, Patterson GA, Trulock EP, Hachem RR. The efficacy of photopheresis for bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant 2010; 29: 424-431.
168. Jaksch P, Scheed A, Keplinger M et al. A prospective interventional study on the use of extracorporeal photopheresis in patients with bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant 2012; 31: 950-957.
169. Greer M, Dierich M, De Wall C et al. Phenotyping established chronic lung allograft dysfunction predicts extracorporeal photopheresis response in lung transplant patients. Inflamm Bowel Dis. 2013; 19(2): 293-300.
170. Meloni F, Cascina A, Miserere S, Perotti C, Vitulo P, Fietta AM. Peripheral CD4(+)CD25(+) TREG cell counts and the response to extracorporeal photopheresis in lung transplant recipients. Transplant Proc 2007; 39: 213-217.
171. Astor TL, Weill D. Extracorporeal photopheresis in lung transplantation. J Cutan Med Surg 2003; 7(4 Suppl): 20-24.
172. Hertz MI, Aurora P, Christie JD et al. Scientific Registry of the International Society for Heart and Lung Transplantation: introduction to the 2010 annual reports. J Heart Lung Transplant 2010; 29: 1083-1088.
173. Stehlik J, Edwards LB, Kucheryavaya AY et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult heart transplant report-2010. J Heart Lung Transplant 2010; 29: 1089-1103.
174. Kirk R, Edwards LB, Kucheryavaya AY et al. The Registry of the International Society for Heart and Lung Transplantation: thirteenth official pediatric heart transplantation report-2010. J Heart Lung Transplant 2010; 29: 1119-1128.
175. Aurora P, Edwards LB, Kucheryavaya AY et al. The Registry of the International Society for Heart and Lung Transplantation: thirteenth official pediatric lung and heart-lung transplantation report-2010. J Heart Lung Transplant 2010; 29: 1129-1141.
176. Schmauss D, Weis M. Cardiac allograft vasculopathy: recent developments. Circulation 2008; 117: 2131-2141.
177. Hertz MI, Aurora P, Benden C et al. Scientific Registry of the International Society for Heart and Lung Transplantation: introduction to the 2011 annual reports. J Heart Lung Transplant 2011; 30: 1071-1077.
178. Stehlik J, Edwards LB, Kucheryavaya AY et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-eighth adult heart transplant report-2011. J Heart Lung Transplant 2011; 30: 1078-1094.
179. Kirk R, Edwards LB, Kucheryavaya AY et al. The Registry of the International Society for Heart and Lung Transplantation: fourteenth pediatric heart transplantation report-2011. J Heart Lung Transplant 2011; 30: 1095-1103.
180. Christie JD, Edwards LB, Kucheryavaya AY et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-eighth adult lung and heart-lung transplant report-2011. J Heart Lung Transplant 2011; 30: 1104-1122.
181. Benden C, Aurora P, Edwards LB et al. The Registry of the International Society for Heart and Lung Transplantation: fourteenth pediatric lung and heart-lung transplantation report-2011. J Heart Lung Transplant 2011; 30: 1123-1132.
182. Barr ML, Meiser BM, Eisen HJ et al. Photopheresis for the prevention of rejection in cardiac transplantation. Photopheresis Transplantation Study Group. N Engl J Med 1998; 339: 1744-1751.
183. Barr ML, Baker CJ, Schenkel FA et al. Prophylactic photopheresis and chronic rejection: effects on graft intimal hyperplasia in cardiac transplantation. Clin Transplant 2000; 14: 162-166.
184. Kirklin JK, Brown RN, Huang ST et al. Rejection with hemodynamic compromise: objective evidence for efficacy of photopheresis. J Heart Lung Transplant 2006; 25: 283-288.
185. Marques MB, Schwartz J. Update on extracorporeal photopheresis in heart and lung transplantation. J Clin Apher 2011; 26: 146-151.
186. Hivelin M, Siemionow M, Grimbert P, Lantieri L. Extracorporeal photopheresis: from solid organs to face transplantation. Transpl Immunol 2009; 21: 117-128.
187. Lehrer MS, Ruchelli E, Olthoff KM, French LE, Rook AH. Successful reversal of recalcitrant hepatic allograft rejection by photopheresis. Liver Transpl 2000; 6: 644-647.
188. Urbani L, Mazzoni A, Catalano G et al. The use of extracorporeal photopheresis for allograft rejection in liver transplant recipients. Transplant Proc 2004; 36: 3068-3070.
189. Urbani L, Mazzoni A, Colombatto P et al. A novel immunosuppressive strategy combined with preemptive antiviral therapy improves the eighteen- month mortality in HCV recipients transplanted with aged livers. Transplantation 2008; 86: 1666-1671.
190. Urbani L, Mazzoni A, Colombatto P et al. Potential applications of extracorporeal photopheresis in liver transplantation. Transplant Proc 2008; 40: 1175-1178.
191. Dall'Amico R, Murer L, Montini G et al. Successful treatment of recurrent rejection in renal transplant patients with photopheresis. J Am Soc Nephrol 1998; 9: 121-127.
192. Baron ED, Heeger PS, Hricik DE, Schulak JA, Tary-Lehmann M, Stevens SR. Immunomodulatory effect of extracorporeal photopheresis after successful treatment of resistant renal allograft rejection. Photodermatol Photoimmunol Photomed 2001; 17: 79-82.
193. Wolfe JT, Tomaszewski JE, Grossman RA et al. Reversal of acute renal allograft rejection by extracorporeal photopheresis: a case presentation and review of the literature. J Clin Apher 1996; 11: 36-41.
194. Genberg H, Kumlien G, Shanwell A, Tyden G. Refractory acute renal allograft rejection successfully treated with photopheresis. Transplant Proc 2005; 37: 3288-3289.
195. Kumlien G, Genberg H, Shanwell A, Tyden G. Photopheresis for the treatment of refractory renal graft rejection. Transplantation 2005; 79: 123-125.
196. Lamioni A, Carsetti R, Legato A et al. Induction of regulatory T cells after prophylactic treatment with photopheresis in renal transplant recipients. Transplantation 2007; 83: 1393-1396.
197. Jardine MJ, Bhandari S, Wyburn KR, Misra AK, McKenzie PR, Eris JM. Photopheresis therapy for problematic renal allograft rejection. J Clin Apher 2009; 24: 161-169.
198. Lai Q, Pretagostini R, Gozzer M et al. Multimodal therapy with combined plasmapheresis, photoapheresis, and intravenous immunoglobulin for acute antibody-mediated renal transplant rejection: a 2-year followup. Transplant Proc 2011; 43: 1039-1041.
199. Urbani L, Mazzoni A, De Simone P et al. Avoiding calcineurin inhibitors in the early post-operative course in high-risk liver transplant recipients: the role of extracorporeal photopheresis. J Clin Apher 2007; 22: 187-194.
200. Kusztal M, Koscielska-Kasprzak K, Gdowska W et al. Extracorporeal photopheresis as an antirejection prophylaxis in kidney transplant recipients: preliminary results. Transplant Proc 2011; 43: 2938-2940.
201. Cosnes J, Cattan S, Blain A et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002; 8: 244-250.
202. Dignass A, Van Assche G, Lindsay JO et al. The second European evidence- based Consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010; 4: 28-62.
203. Reinisch W, Knobler R, Rutgeerts PJ et al. Extracorporeal photopheresis in patients with steroid-dependent Crohn's disease: an open-label, multicenter, prospective trial. Inflamm Bowel Dis 2013; 19(2): 293-300.
204. Danese S, Fiorino G, Reinisch W. Review article: causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-alpha therapy. Aliment Pharmacol Ther 2011; 34: 1-10.
205. Abreu MT, von Tirpitz C, Hardi R et al. Extracorporeal photopheresis for the treatment of refractory Crohn's disease: results of an open-label pilot study. Inflamm Bowel Dis 2009; 15: 829-836.
206. Darsow U, Wollenberg A, Simon D et al. ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 2010; 24: 317-328.
207. Saeki H, Furue M, Furukawa F et al. Guidelines for management of atopic dermatitis. J Dermatol 2009; 36: 563-577.
208. Werfel T, Aberer W, Augustin M et al. Atopic dermatitis: S2 guidelines. J Dtsch Dermatol Ges 2009; 7(Suppl 1): S1-S46.
209. Ou LS, Goleva E, Hall C, Leung DY. T regulatory cells in atopic dermatitis and subversion of their activity by superantigens. J Allergy Clin Immunol 2004; 113: 756-763.
210. Ling EM, Smith T, Nguyen XD et al. Relation of CD4 + CD25 + regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet 2004; 363: 608-615.
211. Di Cesare A, Di Meglio P, Nestle FO. A role for Th17 cells in the immunopathogenesis of atopic dermatitis? J Invest Dermatol 2008; 128: 2569-2571.
212. Louten J, Boniface K, de Waal Malefyt R. Development and function of TH17 cells in health and disease. J Allergy Clin Immunol 2009; 123: 1004-1011.
213. Colver GB, Symons JA, Duff GW. Soluble interleukin 2 receptor in atopic eczema. Br Med J 1989; 298: 1426-1428.
214. Furue M, Koga T, Yamashita N. Soluble E-selectin and eosinophil cationic protein are distinct serum markers that differentially represent clinical features of atopic dermatitis. Br J Dermatol 1999; 140: 67-72.
215. Legat FJ, Hofer A, Brabek E, Quehenberger F, Kerl H, Wolf P. Narrowband UV-B vs medium-dose UV-A1 phototherapy in chronic atopic dermatitis. Arch Dermatol 2003; 139: 223-224.
216. Tzaneva S, Kittler H, Holzer G et al. 5-Methoxypsoralen plus ultraviolet (UV) A is superior to medium-dose UVA1 in the treatment of severe atopic dermatitis: a randomized crossover trial. Br J Dermatol 2010; 162: 655-660.
217. Prinz B, Nachbar F, Plewig G. Treatment of severe atopic dermatitis with extracorporeal photopheresis. Arch Dermatol Res 1994; 287: 48-52.
218. Hjuler KP, Vestergaard C, Deleuran M. A retrospective study of six cases of severe recalcitrant atopic dermatitis treated with long-term extracorporeal photopheresis. Acta Derm Venereol 2010; 90: 635-636.
219. Mohla G, Horvath N, Stevens S. Quality of life improvement in a patient with severe atopic dermatitis treated with photopheresis. J Am Acad Dermatol 1999; 40: 780-782.
220. Wolf P, Georgas D, Tomi NS, Schempp CM, Hoffmann K. Extracorporeal photochemotherapy as systemic monotherapy of severe, refractory atopic dermatitis: results from a prospective trial. Photochem Photobiol Sci 2013; 12: 174-181.
221. Prinz B, Michelsen S, Pfeiffer C, Plewig G. Long-term application of extracorporeal photochemotherapy in severe atopic dermatitis. J Am Acad Dermatol 1999; 40: 577-582.
222. Radenhausen M, Michelsen S, Plewig G, Bechara FG, Altmeyer P, Hoffmann K. Bicentre experience in the treatment of severe generalised atopic dermatitis with extracorporeal photochemotherapy. J Dermatol 2004; 31: 961-970.
223. Radenhausen M, von Kobyletzki G, Hoxtermann S, Altmeyer P, Hoffmann K. Activation markers in severe atopic dermatitis following extracorporeal photochemotherapy. Acta Derm Venereol 2003; 83: 49-50.
224. Richter HI, Billmann-Eberwein C, Grewe M et al. Successful monotherapy of severe and intractable atopic dermatitis by photopheresis. J Am Acad Dermatol 1998; 38: 585-588.
225. Sand M, Bechara FG, Sand D et al. Extracorporeal photopheresis as a treatment for patients with severe, refractory atopic dermatitis. Dermatology 2007; 215: 134-138.
226. Wolf P. Extracorporeal photopheresis in atopic dermatitis. Abstract presented at the 34th Annual Meeting of the American Society for Photobiology, Burlingame, CA, June 20-25 2008.
227. Rubegni P, Poggiali S, Cevenini G et al. Long term follow-up results on severe recalcitrant atopic dermatitis treated with extracorporeal photochemotherapy. J Eur Acad Dermatol Venereol 2013; 27(4): 523-526.
228. Knobler R. Photopheresis and the red man syndrome. Dermatology 1995; 190: 97-98.
229. Zachariae H, Bjerring P, Brodthagen U, Sogaard H. Photopheresis in the red man or pre-Sezary syndrome. Dermatology 1995; 190: 132-135.
230. Hofer A, Mullegger R, Kerl H, Wolf P. Extracorporeal photochemotherapy for the treatment of erythrodermic pityriasis rubra pilaris. Arch Dermatol 1999; 135: 475-476.
231. Wolf P, Mullegger R, Cerroni L et al. Photoaccentuated erythroderma associated with CD4 + T lymphocytopenia: successful treatment with 5-methoxypsoralen and UVA, interferon alfa-2b, and extracorporeal photopheresis. J Am Acad Dermatol 1996; 35: 291-294.
232. Ring J, Alomar A, Bieber T et al. EDF Guideline. Guidelines for treatment of atopic eczema (atopic dermatitis). URL http://www.euroderm. org/images/stories/guidelines/GuidelinesTreatmentAtopicEczema.pdf (last accessed: 30 October 2013).
233. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.
234. Holm EA, Wulf HC, Stegmann H, Jemec GB. Life quality assessment among patients with atopic eczema. Br J Dermatol 2006; 154: 719-725.
235. Rehal B, Armstrong A. Health outcome measures in atopic dermatitis: a systematic review of trends in disease severity and quality-of-life instruments 1985-2010. PLoS ONE 2011; 6: e17520.
236. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
237. Bojestig M, Arnqvist HJ, Hermansson G, Karlberg BE, Ludvigsson J. Declining incidence of nephropathy in insulin-dependent diabetes mellitus. N Engl J Med 1994; 330: 15-18.
238. Madsbad S, Alberti KG, Binder C et al. Role of residual insulin secretion in protecting against ketoacidosis in insulin-dependent diabetes. Br Med J 1979; 2: 1257-1259.
239. Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003; 26: 832-836.
240. Butler PC, Meier JJ, Butler AE, Bhushan A. The replication of beta cells in normal physiology, in disease and for therapy. Nat Clin Pract Endocrinol Metab 2007; 3: 758-768.
241. Winter WE, Schatz DA. Autoimmune markers in diabetes. Clin Chem 2011; 57: 168-175.
242. Mandrup-Poulsen T, Nerup J, Stiller CR et al. Disappearance and reappearance of islet cell cytoplasmic antibodies in cyclosporin-treated insulin- dependent diabetics. Lancet 1985; 1: 599-602.
243. Bougneres PF, Carel JC, Castano L et al. Factors associated with early remission of type I diabetes in children treated with cyclosporine. N Engl J Med 1988; 318: 663-670.
244. Coutant R, Landais P, Rosilio M et al. Low dose linomide in Type I juvenile diabetes of recent onset: a randomised placebo-controlled double blind trial. Diabetologia 1998; 41: 1040-1046.
245. Herold KC, Gitelman SE, Masharani U et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005; 54: 1763-1769.
246. Keymeulen B, Vandemeulebroucke E, Ziegler AG et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005; 352: 2598-2608.
247. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009; 361: 2143-2152.
248. Xia CQ, Chernatynskaya A, Lai Y, Campbell KA, Clare-Salzler MJ. Experimental extracorporeal photopheresis therapy significantly delays the development of diabetes in non-obese diabetic mice. Clin Immunol 2010; 135: 374-383.
249. Rook AH, Jegasothy BV, Heald P et al. Extracorporeal photochemotherapy for drug-resistant pemphigus vulgaris. Ann Intern Med 1990; 112: 303-305.
250. Gollnick HP, Owsianowski M, Taube KM, Orfanos CE. Unresponsive severe generalized pemphigus vulgaris successfully controlled by extracorporeal photopheresis. J Am Acad Dermatol 1993; 28: 122-124.
251. Wollina U, Lange D, Looks A. Short-time extracorporeal photochemotherapy in the treatment of drug-resistant autoimmune bullous diseases. Dermatology 1999; 198: 140-144.
252. Liang G, Nahass G, Kerdel FA. Pemphigus vulgaris treated with photopheresis. J Am Acad Dermatol 1992; 26: 779-780.
253. Azana JM, de Misa RF, Harto A, Ledo A, Espana A. Severe pemphigus foliaceus treated with extracorporeal photochemotherapy. Arch Dermatol 1997; 133: 287-289.
254. Sanli H, Akay BN, Ayyildiz E, Anadolu R, Ilhan O. Remission of severe autoimmune bullous disorders induced by long-term extracorporeal photochemotherapy. Transfus Apher Sci 2010; 43: 353-359.
255. Licht-Mbalyohere A, Heller A, Stadler R. Extracorporeal photochemotherapy of therapy-refractory cases of systemic lupus erythematosus with urticarial vasculitis and pemphigus foliaceus. Eur J Dermatol 1996; 6: 106-109.
256. Harman KE, Albert S, Black MM. British Association of Dermatologists. Guidelines for the management of pemphigus vulgaris. Br J Dermatol 2003; 149: 926-937.
257. Daniel BS, Hertl M, Werth VP, Eming R, Murrell DF. Severity score indexes for blistering diseases. Clin Dermatol 2012; 30: 108-113.
258. Miller JL, Stricklin GP, Fine JD, King LE, Arzubiaga MC, Ellis DL. Remission of severe epidermolysis bullosa acquisita induced by extracorporeal photochemotherapy. Br J Dermatol 1995; 133: 467-471.
259. Gordon KB, Chan LS, Woodley DT. Treatment of refractory epidermolysis bullosa acquisita with extracorporeal photochemotherapy. Br J Dermatol 1997; 136: 415-420.
260. Camara A, Becherel PA, Bussel A et al. Resistant acquired bullous epidermolysis with severe ocular involvement: the success of extracorporeal photochemotherapy. Ann Dermatol Venereol 1999; 126: 612-615.
261. Becherel PA, Bussel A, Chosidow O, Rabian C, Piette JC, Frances C. Extracorporeal photochemotherapy for chronic erosive lichen planus. Lancet 1998; 351: 805.
262. Kunte C, Erlenkeuser-Uebelhoer I, Michelsen S, Scheerer-Dhungel K, Plewig G. Treatment of therapy-resistant erosive oral lichen planus with extracorporeal photopheresis (ECP). J Dtsch Dermatol Ges 2005; 3: 889-894.
263. Marchesseau-Merlin AS, Perea R, Kanold J, Demeocq F, Souteyrand P, D'Incan M. Photopheresis: an alternative therapeutic approach in corticoresistant erosive oral lichen planus. Ann Dermatol Venereol 2008; 135: 209-212.
264. Elewa R, Altenburg A, Zouboulis CC. Recalcitrant severe erosive cutaneous lichen planus treated with extracorporeal photopheresis monotherapy. Br J Dermatol 2011; 165: 441-443.
265. Zingoni A, Deboli T, Savoia P, Bernengo MG. Effectiveness of extracorporeal photochemotherapy in the treatment of a case of refractory erosive lichen planus. J Dermatol Treat 2010; 21: 119-121.
266. Guyot AD, Farhi D, Ingen-Housz-Oro S et al. Treatment of refractory erosive oral lichen planus with extracorporeal photochemotherapy: 12 cases. Br J Dermatol 2007; 156: 553-556.
267. Chiesa-Fuxench ZC, Gonzalez-Chavez J. Extracorporeal photopheresis: a review on the immunological aspects and clinical applications. P R Health Sci J 2010; 29: 337-347.
268. Bertsias G, Ioannidis JP, Boletis J et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008; 67: 195-205.
269. Wallace DJ. Advances in drug therapy for systemic lupus erythematosus. BMC Med 2010; 8: 77.
270. Knobler RM, Graninger W, Graninger W, Lindmaier A, Trautinger F, Smolen JS. Extracorporeal photochemotherapy for the treatment of systemic lupus erythematosus. A pilot study. Arthritis Rheum 1992; 35: 319-324.
271. Wollina U, Looks A. Extracorporeal photochemotherapy in cutaneous lupus erythematosus. J Eur Acad Dermatol Venereol 1999; 13: 127-130.
272. Richard MA, Saadallah S, Lefevre P, Poullin P, Buscaylet S, Grob JJ. Extracorporeal photochemotherapy in therapy-refractory subacute lupus. Ann Dermatol Venereol 2002; 129: 1023-1026.
273. Boeckler P, Liu V, Lipsker D. Extracorporeal photopheresis in recalcitrant lupus erythematosus. Clin Exp Dermatol 2009; 34: e295-e296.
274. Morruzzi C, Liu V, Bohbot A, Cribier B, Lipsker D. Four cases of photopheresis treatment for cutaneous lupus erythematosus refractory to standard therapy. Ann Dermatol Venereol 2009; 136: 861-867.
275. Richter HI, Krutmann J, Goerz G. Extracorporeal photopheresis in therapy- refractory disseminated discoid lupus erythematosus. Hautarzt 1998; 49: 487-491.
276. Wilfert H, Honigsmann H, Steiner G, Smolen J, Wolff K. Treatment of psoriatic arthritis by extracorporeal photochemotherapy. Br J Dermatol 1990; 122: 225-232.
277. Malawista SE, Trock DH, Edelson RL. Treatment of rheumatoid arthritis by extracorporeal photochemotherapy. A pilot study. Arthritis Rheum 1991; 34: 646-654.
278. Menkes CJ, Andreu G, Heshmati F, Hilliquin P. Extracorporeal photochemotherapy. Br J Rheumatol 1992; 31: 789-790.
279. Hilliquin P, Andreu G, Heshmati F, Menkes CJ. Treatment of refractory rheumatoid polyarthritis by extracorporeal photochemotherapy. Rev Rhum Ed Fr 1993; 60: 125-130.
280. Poehlau D, Rieks M, Postert T et al. Photopheresis-a possible treatment of multiple sclerosis?: report of two cases. J Clin Apher 1997; 12: 154-155.
281. Rostami AM, Sater RA, Bird SJ et al. A double-blind, placebo-controlled trial of extracorporeal photopheresis in chronic progressive multiple sclerosis. Mult Scler 1999; 5: 198-203.
282. Besnier DP, Chabannes D, Mussini JM, Dupas B, Esnault VL. Extracorporeal photochemotherapy for secondary chronic progressive multiple sclerosis: a pilot study. Photodermatol Photoimmunol Photomed 2002; 18: 36-41.
283. Cavaletti G, Perseghin P, Dassi M et al. Extracorporeal photochemotherapy: a safety and tolerability pilot study with preliminary efficacy results in refractory relapsing-remitting multiple sclerosis. Neurol Sci 2006; 27: 24-32.
284. Gilliet M, Cozzio A, Burg G, Nestle FO. Successful treatment of three cases of nephrogenic fibrosing dermopathy with extracorporeal photopheresis. Br J Dermatol 2005; 152: 531-536.
285. Mathur K, Morris S, Deighan C, Green R, Douglas KW. Extracorporeal photopheresis improves nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: three case reports and review of literature. J Clin Apher 2008; 23: 144-150.
286. Lauchli S, Zortea-Caflisch C, Nestle FO, Burg G, Kempf W. Nephrogenic fibrosing dermopathy treated with extracorporeal photopheresis. Dermatology 2004; 208: 278-280.
287. Durani BK, Bock M, Naher H. Extracorporeal photopheresis-treatment option in scleromyxedema? Hautarzt 2001; 52: 938-941.
288. Krasagakis K, Zouboulis CC, Owsianowski M et al. Remission of scleromyxoedema following treatment with extracorporeal photopheresis. Br J Dermatol 1996; 135: 463-466.
289. Nagatani T, Matsuzaki T, Kim S et al. Treatment of cutaneous T-cell lymphomas (CTCL) with extracorporeal photochemotherapy-preliminary report. J Dermatol 1990; 17: 737-745.
290. Zic J, Arzubiaga C, Salhany KE et al. Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol 1992; 27: 729-736.
291. Koh H, Davis B, Meola T, Lim H. Extracorporeal photopheresis for the treatment of 34 patients with cutaneous T-cell lymphoma. J Invest Dermatol 1994; 102: 567(abstract).
292. Prinz B, Behrens W, Holzle E, Plewig G. Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma-the Dusseldorf and Munich experience. Arch Dermatol Res 1995; 287: 621-626.
293. Duvic M, Hester JP, Lemak NA. Photopheresis therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 1996; 35: 573-579.
294. Stevens S, Masten S, Oberhelman-Brag L et al. Circulating CD4 + CD7- lymphocyte burden, CD4 + /CD8 ratio and rapidity of response are predictors of outcome in the treatment of CTCL with extracorporeal photochemotherapy. Photodermatol Photoimmunol Photomed 1996; 12: 36 (abstract).
295. Konstantinow A, Balda B. Treatment of cutaneous T-cell lymphoma with extracorporeal photochemotherapy. J Eur Acad Dermatol Venereol 1997; 9: 111-117.
296. Miracco C, Rubegni P, De Aloe G et al. Extracorporeal photochemotherapy induces apoptosis of infiltrating lymphoid cells in patients with mycosis fungoides in early stages. A quantitative histological study. Br J Dermatol 1997; 137: 549-557.
297. Russell-Jones R, Fraser-Andrews E, Spittle M, Whittaker S. Extracorporeal photopheresis in Sezary syndrome. Lancet 1997; 350: 886.
298. Vonderheid EC, Zhang Q, Lessin SR et al. Use of serum soluble interleukin- 2 receptor levels to monitor the progression of cutaneous T-cell lymphoma. J Am Acad Dermatol 1998; 38: 207-220.
299. Zouboulis CC, Schmuth M, Doepfmer S, Dippel E, Orfanos CE. Extracorporeal photopheresis of cutaneous T-cell lymphoma is associated with reduction of peripheral CD4 + T lymphocytes. Dermatology 1998; 196: 305-308.
300. Jiang SB, Dietz SB, Kim M, Lim HW. Extracorporeal photochemotherapy for cutaneous T-cell lymphoma: a 9.7-year experience. Photodermatol Photoimmunol Photomed 1999; 15: 161-165.
301. Crovetti G, Carabelli A, Berti E et al. Photopheresis in cutaneous T-cell lymphoma: five-year experience. Int J Artif Organs 2000; 23: 55-62.
302. Wollina U, Liebold K, Kaatz M, Looks A, Stuhlert A, Lange D. Survival of patients with cutaneous T-cell lymphoma after treatment with extracorporeal photochemotherapy. Oncol Rep 2000; 7: 1197-1201.
303. Bouwhuis SA, el-Azhary RA, McEvoy MT et al. Treatment of late-stage Sezary syndrome with 2-Chlorodeoxyadenosine. Int J Dermatol 2002; 41: 352-356.
304. Knobler E, Warmuth I, Cocco C, Miller B, Mackay J. Extracorporeal photochemotherapy-the Columbia Presbyterian experience. Photodermatol Photoimmunol Photomed 2002; 18: 232-237.
305. Quaglino P, Fierro MT, Rossotto GL, Savoia P, Bernengo MG. Treatment of advanced mycosis fungoides/Sezary syndrome with fludarabine and potential adjunctive benefit to subsequent extracorporeal photochemotherapy. Br J Dermatol 2004; 150: 327-336.
306. de Misa RF, Harto A, Azana JM, Belmar P, Diez E, Ledo A. Photopheresis does not improve survival in Sezary syndrome patients with bone marrow involvement. J Am Acad Dermatol 2005; 53: 171-172.
307. Rao V, Ryggen K, Aarhaug M, Dai HY, Jorstad S, Moen T. Extracorporeal photochemotherapy in patients with cutaneous T-cell lymphoma: is clinical response predictable? J Eur Acad Dermatol Venereol 2006; 20: 1100-1107.
308. Gasova Z, Spisek R, Dolezalova L, Marinov I, Vitek A. Extracorporeal photochemotherapy (ECP) in treatment of patients with c-GVHD and CTCL. Transfus Apher Sci 2007; 36: 149-158.